Browse by ▼

Dawn Anderson

All Posts

  • Is J&J a Good Buy?

    By Dawn Anderson - February 23, 2012 | Tickers: GSK, JNJ, MRK, SNY

    After two years of rampant recalls, Johnson and Johnson (NYSE: JNJ) has announced their CEO Bill Weldon will step down in April. He is being replaced by Alex Gorsky, J&J’s head of pharmaceuticals in Europe, the Middle East and Africa. Weldon will remain the company’s chairman. While J&J’s sterling reputation may have been tarnished, surprisingly its stock price has been in an upward swing over more »

  • Cloud Computing's Role in 2012

    By Dawn Anderson - January 24, 2012 | Tickers: RAX

    According to Pew Research Center’s Internet & American Life Project, tablet and e-reader ownership almost doubled over the holidays. Currently 1 out of every 4 Americans now owns such a device and demand continues to grow as an array of content has been developed for them. Consumers are becoming thirsty for content and providers are beginning to utilize Cloud-based technologies in order to give them access to their content on more »

  • Genworth Financial's Growth Potential

    By Dawn Anderson - January 24, 2012 | Tickers: GNW

    In spite of the market turmoil annuities managed to do surprisingly well for investors. Although annuities are often frowned upon because of high fees and low returns, holders of annuity investments managed to ride out the market without suffering major losses. Insurers did not seem to fair as well and many of them exited the variable annuities market. In 2012, we are now starting to see many players, both old more »

  • Investing in Big Pharma: Is Eli Lilly the answer?

    By Dawn Anderson - December 23, 2011 | Tickers: LLY, MRK

    Eli Lilly (NYSE: LLY) is considered by some analysts to be a good investment for 2012. Sure their stock has done respectably, they have tons of cash and their pipeline is full, but how about their goodwill? While they have received some positive press in recent months, one can’t help but wonder how damaging the recent wave of pending litigation will alter their future.

    Lilly, along with co-defendant Takeda more »